Background. Damaging inflammation is thought to contribute to the high morbidity and mortality of tuberculous meningitis (TBM), but the link between inflammation and outcome remains unclear.
Meningitis is the most severe manifestation of tuberculosis, resulting in death or neurological disability in >30% of adult patients [1, 2] . Previously identified factors associated with mortality of tuberculous meningitis (TBM) include disease severity at the time of presentation, drug resistance, human immunodeficiency virus (HIV) infection, low CD4 + T-cell counts among those HIV-infected individuals, and low cerebrospinal fluid (CSF) cell counts and glucose level [1] [2] [3] [4] [5] . In addition, it has long been suggested that inflammation contributes to poor outcome of TBM, and adjuvant corticosteroids have shown to reduce mortality due to TBM [6] .
The exact nature of the detrimental inflammatory response in TBM, however, remains unclear. A lower CSF cell count was associated with increased mortality among patients with TBM in Vietnam [3] but not those in China [7] or South Africa [8] .
The type of CSF cells may be important. On average, 70%-90% of cells in the CSF are mononuclear cells [2, 9] , mainly lymphocytes [10] , but up to one third of patients show a predominance of neutrophils [11] . Interestingly, among HIV-infected patients in South Africa, CSF neutrophil counts predicted the occurrence of TBM immune reconstitution inflammatory syndrome (IRIS) [12] . However, in HIV-negative patients with TBM, there are no published data relating CSF neutrophil counts with immunopathology or mortality.
A recent study linked leukotriene A4 hydrolase (LTA4H) rs17525495 genotype to CSF leukocyte count and patient survival. LTA4H converts instable leukotriene A4 (LTA4) to the stable proinflammatory LTB4, and Vietnamese patients with TBM with the gain-of-function TT LTA4H genotype showed a higher CSF leukocyte count and better survival with adjuvant corticosteroids, while patients bearing the hypoinflammatory CC variant showed lower CSF cell numbers and no or even a negative effect of corticosteroids [13] . To date, no other study has examined the effect of this LTA4H genotype on the CSF inflammatory profile and survival rate among individuals with TBM.
Adjunctive therapy is topic of intensive research in tuberculosis [14] . Corticosteroids have a proven role in TBM [6] , while a range of other immunomodulatory drugs, such as thalidomide [15] , anti-tumor necrosis factor, and recombinant interferon γ, have been used sporadically [16] . Better understanding of the immune-mediated pathogenesis of TBM is crucial to the development of more-effective adjunctive therapy. Therefore, we examined clinical parameters, routine CSF and blood hematology markers, and LTA4H genotype in relation to survival among patients with TBM.
METHODS

Setting and Patients
In this prospective cohort study, we included all patients >14 years of age who presented with suspected TBM between October 2006 and June 2016 in a referral hospital in Bandung, Indonesia. Patients were suspected as having TBM when they presented with subacute illness including headache, fever or focal neurological symptoms, irrespective of the presence or absence of pulmonary, or other extrapulmonary tuberculosis. Patients underwent standardized screening that included CSF examination and chest radiography. The neurological status of patients with TBM was classified according to modification of the British Medical Research Council (BMRC) definition, as follows: grade I, normal consciousness, no neurological signs; grade II, Glasgow Coma Scale (GCS) score of 11-14 or 15 with neurological signs; and grade III, GCS score of ≤10 [17] . All patients were tested for HIV; retrospective HIV testing was done anonymously for those patients who died before consent was obtained or who were admitted before routine HIV testing was implemented in 2009. The study was part of the project titled "Optimization of Diagnosis of Meningitis, " approved by the Ethical Committee of Hasan Sadikin Hospital/Faculty of Medicine of Universitas Padjadjaran, Bandung, Indonesia. A subset of patients in this study was included in one of 3 randomized, clinical trial evaluating intensified antibiotic treatment, for which separate ethical approval was obtained (clinical trials registration NCT02169882) [18, 19] .
Microbiological Testing
Microbiological diagnosis of TBM was done using microscopy, solid Ogawa culture, and liquid commercial culture, as well as using microscopic observation drug susceptibility assay (a liquid culture) [20] after 2010. Four to 10 mL of CSF is concentrated by centrifugation at 3000×g for 15 minutes, and CSF sediment is used for microscopy and culture. IS6110 Polymerase chain reaction (PCR) was performed retrospectively for a subset of 230 samples [21] , and Gene Xpert MTB/RIF has been used since 2015. Drug resistance testing is otherwise not routinely available in our setting, but genotypic drug resistance was measured through whole-genome sequencing in 102 patients. Further microbiological testing included CSF microscopy and culture for detection of bacteria and fungi, as well as cryptococcal antigen testing among those who were HIV infected. CSF real-time PCR and serological testing for Toxoplasma gondii was performed retrospectively for HIV-infected patients [22] .
Treatment and Follow-up
TBM was treated with a combination of rifampicin (450 mg, corresponding to approximately 10 mg/kg), isoniazid (300 mg), ethambutol (750 mg), and pyrazinamide (1500 mg) for 6 months. For unconscious patients, drugs were given by nasogastric tube. As part of 2 published pharmacokinetic studies [18, 23] and 1 ongoing randomized controlled trial (clinical trials registration NCT02169882), 47 patients received high-dose rifampicin, and 25 patients received moxifloxacin instead of ethambutol. Patients were given adjunctive dexamethasone, following the internationally accepted 6-week tapering regimen, starting at 0.3 mg/kg for grade I and 0.4 mg/kg for grade II/ III TBM [3] , and switching to an equivalent dose of oral prednisolone in case of early discharge. Patients with newly diagnosed HIV infection initiated treatment with efavirenz-based antiretroviral treatment 4-8 weeks after the start of tuberculosis treatment [24] . Patients were followed prospectively for at least 1 year. Field physicians or nurses made telephone calls, and a social worker conducted home visits for patients not returning after hospital discharge. Death after hospital discharge was assessed by interview of family members and retrieval of patients' death certificates from local authorities.
LTA4H Genotyping
Genotyping for the rs17525495 LTA4H single-nucleotide polymorphism was performed using the TaqMan C__25593629_10 assay on the 7300 ABI real-time PCR system (Applied Biosystems, Foster City, CA). Samples with an indeterminate allele call could be assigned in a second run except for one, resulting in a final 99.8% call rate.
Case Definitions
Most patients with meningitis in this setting present with subacute disease, and tuberculosis is the commonest cause [1] . TBM was classified as definite if either CSF microscopy for acid-fast bacilli, Mycobacterium tuberculosis culture, or PCR results were positive. Diagnosis of cerebral toxoplasmosis was based on findings of toxoplasma PCR or neuroimaging [22] , confirmation of cryptococcal meningitis by India ink staining or cryptococcal antigen testing [25] , and confirmation of acute bacterial meningitis by Gram staining. Based on prior evaluation of CSF characteristics of definite and clinically suspected cases in this cohort, patients were classified as having probable TBM if they had a CSF to blood glucose ratio of <0.5 combined with a CSF cell count ≥5 cells/μL. Patients for whom no alternative diagnosis was made and who presented with a CSF leukocyte count of <5 /μL were classified as having no meningitis. All remaining patients were classified as having an unknown diagnosis. Not all information listed in the recent consensus-based research definition for TBM [26] was available, and a score suggesting probable meningitis according to this definition (a score of ≥10 points in the absence of neuroimaging findings) was found for 36% of patients without meningitis and 41.2% of those without a diagnosis according to our classification. For the purpose of this study, we therefore chose our own, somewhat more specific case definition for probable TBM.
Data Analysis and Statistics
Patient characteristics, presented as median values (with interquartile ranges) or proportions, as indicated, were compared between HIV-infected and noninfected patients, and subsequent analyses were restricted to HIV-negative patients. Only patients with complete data for the respective variables were included for each analysis, as indicated in the legends of figures and tables. Kaplan-Meier curves were used to illustrate survival over time, with continuous predictors divided into 3 groups, with cutoffs allowed to deviate slightly from exact tertiles to improve interpretability of results. GCS score was treated as a continuous variable to avoid loss of power by stratification. All analyses were performed with RStudio in R 3.3.1., using ggplot2, reshape2, dplyr, openxlsx, tableone, survminer, and Hmisc. Univariate and multivariate Cox regression was performed using survival, and hazard ratios (HRs), as well as the results of log-likelihood ratio tests, were reported. CSF cell counts and protein levels were positively skewed and therefore log transformed, using a log 10 [x + 1] transformation to avoid having to exclude patients from regression analysis in whom either CSF cell counts or CSF protein levels were 0. Sensitivity analyses were performed excluding culture-negative cases, patients who did not start on corticosteroids, patients who participated in a trial, and patients with known drug-resistant M. tuberculosis. Secondary analysis was done to distinguish early and delayed mortality, with early and late definitions based on the median time to death, to ensure equal power for both groups. Secondary analysis for the genetic analysis involved a recessive model comparing the LTA4H TT genotype against the CC/CT genotypes combined. A correlation matrix was made using corrplot, with Spearman ranking, on pair-wise-complete observations of all continuous variables. Multivariate analysis was performed as secondary analysis to explore dependence of predictors for clinical, CSF, and blood variables separately, entering variables with P values of <.1 in univariate analysis in the model.
RESULTS
Clinical Presentation and Patient Mortality
From 1186 patients with clinically suspected meningitis, we excluded 156 with incomplete baseline data, 171 with no meningitis or an alternative diagnosis, and 215 with no final diagnosis. This left 608 patients with TBM for further analysis, including 55.3% with culture-confirmed TBM and 11.0% with TBM confirmed by in-house PCR or Gene Xpert. Patients generally presented with BMRC grade II (73.7%) or grade III (14.5%) TBM, 52.0% had motor abnormalities, and 59.7% cranial nerve palsy. Ninety-three patients (15.3%) were HIV infected, presenting with severe disease, with available median CD4 + T-cell counts of 62 cells/µL blood (IQR 43-186) in 2014-2016. CSF examination showed typical abnormalities with elevated cell count and protein, and low glucose, especially among HIV-negative patients (Table 1) . Follow-up data were complete for 91.5% of patients at 1 month and for 73.2% at 1 year. Oneyear mortality of patients with TBM was very high, with values of 60.0% (95% confidence interval [CI], 47.8%-69.9%) for HIVinfected patients and 40.7% (95% CI, 36.1%-45.1%) for HIVuninfected patients (HR, 1.99; 95% CI, 1.46-2.72; Figure 1A) , with a median time to death of 4 and 6 days after start of treatment, respectively. As expected, those with the lowest GCS score had the highest mortality (data for 447 HIV-negative patients are shown in Figure 1B ). We could not analyze an effect of adjuvant corticosteroid therapy because virtually all patients (91%, based on review of individual case records) received corticosteroids. Isoniazid and/or rifampicin resistance (detected in 9 patients) was too infrequent to be analyzed separately. The same was true for the use of high-dose rifampicin (for 47 patients) or moxifloxacin instead of ethambutol (for 25).
Baseline Clinical and Laboratory Parameters as Predictors for Death
We restricted further analysis to the 515 HIV-negative patients because of large differences between HIV-infected patients and noninfected patients in terms of survival and laboratory parameters and the relatively small number (n = 93) of HIVinfected patients. Like GCS score, BMRC TBM grade was a very strong predictor of survival (Table 2) . Motor abnormalities and increased body temperature (Figure 2A ) also predicted mortality; risk estimates for these clinical markers were higher for early (0-6 days) as compared to late (7-365 days) mortality (Supplementary Table 1) .
A focus on CSF characteristics revealed that a low CSF to blood glucose ratio ( Figure 2B) and an elevated protein level were associated with death in univariate Cox regression, while the total CSF leukocyte count was not. However, a 10% increase in the proportion of neutrophils among CSF leukocytes was associated with a 10% increase in the hazard for mortality. The sensitivity analysis in culture-confirmed cases showed that both an increased neutrophil percentage and increased neutrophil count increased the risk of mortality. This indicates that neutrophils, rather than a decrease in the number of mononuclear cells, are responsible for this effect. Patients with a CSF neutrophil percentage of >50% had a particularly high risk of dying ( Figure 2C ). Interestingly, a low glucose ratio was more strongly associated with delayed than with early mortality, while CSF neutrophil proportion similarly predicted early and late mortality (Supplementary Table 1 ). Similar or slightly higher risk estimates were found when the analysis was restricted to patients with a CSF culture positive for M. tuberculosis (Table 2) . By itself, a CSF culture positive for M. tuberculosis, reflecting a higher bacillary load, was associated with an estimated 1-year mortality of 44.4% (95% CI, 35.5%-47.3%), compared with 34.8% (95% CI, 27.7%-41.2%) for a CSF culture negative for M. tuberculosis.
Blood neutrophilia ( Figure 2D ) and corresponding leukocytosis were associated with higher mortality. In this analysis-still restricted to HIV-uninfected patients-patients with <1.3 × 10 9 lymphocytes/L and those with low (<0.30 × 10 9 monocytes/L) or high (≥0.60 × 10 9 monocytes/L) monocyte counts showed a higher risk of dying. In secondary analysis, the monocyte to lymphocyte ratio, which has been linked to M. tuberculosis susceptibility [27] , was associated with mortality, as well (HR, 1.24; 95% CI, 1.03-1.51; Supplementary  Figure 1 ). Risk estimates for blood markers were similar for early and delayed mortality (Supplementary Table 1 ).
LTA4H Genotype
Among 427 HIV-uninfected patients, 56.2% had a CC, 35.6% a CT, and 8.2% had a TT rs17525495 LTA4H genotype (Table  3) . Clinical characteristics except for sex were not associated with genotype, but median CSF mononuclear cell counts were different (91 cells/μL in the TT genotype group versus 65 cells/μL in the TC genotype group and 109 cells/μL in the CC genotype group). Total CSF leukocyte count, neutrophil level, protein level, and CSF to blood glucose ratio were not associated with genotype. The percentage of patients with positive culture results decreased as a function of the presence of the T allele (P = .013), which is considered to be proinflammatory. LTA4H genotype was not associated with a difference in patient survival in univariate Cox regression analysis (Table  2 ) also in sensitivity analyses excluding 177 patients with negative CSF culture (P = .585), 6 who had not received corticosteroids (P = .845), 9 who had isoniazid and/or rifampicin drug-resistant TBM (P = .805), or 85 who participated in a trial (P = .740). In a secondary analysis applying a recessive model, we increased power by combining patients with CC or CT genotypes and compared them to those with the TT genotype: the TT genotype had a nonsignificant protective effect (HR, 0.91; 95% CI, .52-1.60), with a similar effect after adjustment for sex and age (HR, 0.86; 95% CI, .49-1.52) and an increased but still not significant effect after adjustment for GCS score (HR, 0.71; 95% CI, .38-1.36). Indeed, among 175 patients with milder disease (GCS score, 14-15), those with the TT genotype showed a trend toward better survival as compared to the combined group with the CC or CT genotype (Supplementary Figure 2) .
Prognostic Markers-Correlation and Multivariate Cox Regression
Analysis
We next examined the correlation of clinical, CSF, and blood parameters linked with death. Fever, GCS, and motor abnormalities showed no correlation with one another and were independently associated with mortality in Cox regression ( Figure 3 and Table 4 ). CSF neutrophil percentage, protein levels, and glucose levels showed moderate correlation, and independently predicted death in multivariate analysis, while culture positivity did not (Table 4) . CSF markers showed only a weak correlation with blood leukocyte counts. Blood neutrophil count was the sole blood inflammatory marker independently associated with death in a Cox regression model (neutrophil count correlates strongly with blood total leukocyte count and is the product of total leukocyte count and blood neutrophil percentage, both of which were not included in the model; Table 4 ). Correlation matrices were similar for patients who died and those who survived the first year (data not shown). 
DISCUSSION
In a prospectively followed cohort of 608 tuberculous meningitis patients in Indonesia, 1-year mortality was 43.7%. Mortality was linked with previously reported risk factors (HIV infection, disease severity, neurological complications, and low CSF glucose level) and several newly identified factors, including fever, CSF culture positivity, a predominance of neutrophils in CSF, and a high blood monocyte to lymphocyte ratio. Unlike a previous study in Vietnam, we found no relation between the LTA4H promoter polymorphism rs17525495 and outcome. TBM is relatively rare but responsible for a disproportionate number of deaths due to tuberculosis. Most studies are either relatively small or compromised by low rates of bacteriological confirmation. Two large clinical trials conducted in Vietnam reported a 9-month mortality of 31.8% [3] and 27.9% [2] for patients who received dexamethasone and standard-dose rifampicin. Mortality in our cohort is higher (42.6% at 9 months), possibly because 83% of our patients were not included in a clinical trial or because our patients present with more-advanced disease; the proportion of patients with grade I disease was 12.0% in our cohort, compared with 32.3% and 39.1% in Vietnam. HIV was associated with a 2-fold higher risk of death in this study, underlining the importance of early HIV diagnosis and treatment [1] .
Because HIV strongly influences inflammatory phenotype and mortality, we concentrated further analysis on HIV-uninfected cases, making it the largest study on predictors of death in this group, with 67% of cases bacteriologically confirmed and extensive follow-up. Our data clearly show that neurological complications, especially motor abnormalities, are strongly predictive of a poor outcome of TBM. Not unexpectedly, these risk factors weighed strongest for early mortality. Half of deaths in our cohort occurred in the first 6 days after the start of treatment, mostly among those with the most-advanced stage of disease, again reflecting the importance of earlier diagnosis and treatment.
We are the first to report that febrile patients have a higher risk of dying of TBM. Fever may reflect damaging inflammation or increased metabolism of a damaged brain, as has been suggested by increased mortality of stroke patients with fever [28] . Further study should determine whether aggressive reduction of fever, as advocated in an excellent review on acute care management of TBM [29] , can improve the outcome of TBM. Of note, mild hypothermia showed no benefit and even seemed harmful in a randomized controlled trial in patients with acute bacterial meningitis [30] . Evaluation of CSF markers revealed that high neutrophil counts strongly predicted mortality, while we did not find a higher fraction of neutrophils in patients with a short duration of disease (data not shown), unlike one earlier case series [10] . Neutrophils are capable of killing M. tuberculosis but may also play a detrimental role in tuberculosis [31] . Like in the lung [32] , M. tuberculosis can also infect neutrophils in the CSF [33] . Interestingly, a higher proportion of CSF neutrophils was associated with CSF culture positivity in studies from Vietnam [34] and Brazil [35] and with the occurrence of IRIS in South Africa [12] . High blood neutrophil counts, which did not correlate with CSF neutrophil counts, also predicted death due to TBM. The association of a high monocyte to lymphocyte ratio to death provides further support for a possible detrimental role of a dysregulated innate immune response in TBM. Of course, we should be careful about inferring a causal role for neutrophils in TBM-associated death, as higher CSF neutrophil counts might also be an epiphenomenon of unfavorable biological processes taking place during TBM. Clearly, the possible detrimental role of neutrophils in patients with TBM needs more study. We confirmed that a low CSF to blood glucose ratio was associated with mortality, in line with sepsis studies linking cellular metabolism and death [36] . Our study also supports intensified antibiotic treatment as a beneficial strategy, as patients with a CSF culture positive for M. tuberculosis had a 37% increased hazard for mortality. In a recent randomized controlled trial, we found that high-dose rifampicin administered intravenously, to compensate for poor CSF penetration of rifampicin, was associated with reduced mortality (HR, 0.42; 95% CI, .2-.91) [18] . A larger randomized controlled trial in Vietnam failed to see an effect of a higher dose of oral rifampicin [2] , but this may have been due to the modest dose increase in that study [37] .
It was recently shown that a polymorphism in LTA4H correlated with CSF leukocyte count and survival among 182 Vietnamese patients with TBM [13] . This same LTA4H genotype was not associated with CSF leukocyte count or with survival in Figure 3 . Correlation matrix for clinical and inflammatory markers in human immunodeficiency virus-negative patients with tuberculous meningitis. The correlation matrix was made with Spearman ranking, using pair-wise-complete observations. Abbreviation: GCS, Glasgow Coma Scale. Multivariate Cox regression for survival including variables with a P value of < .1 in univariate analysis for 365-day mortality. Three separate models were run: for analysis of clinical variables, 412 patients had complete data; for analysis of CSF inflammatory markers, 464 had complete data; and for analysis of blood inflammatory markers, 327 had complete data available.
Abbreviations: CI, confidence interval; CSF, cerebrospinal fluid; GCS, Glasgow Coma Scale; HR, hazard ratio. a Values of <.05 are considered statistically significant.
b Neutrophil percentage was used because of its more common use in clinical practice and its stronger association as compared to count.
c Neutrophil count was used being the multiplication of neutrophil concentration and total leukocyte count (both univariate predictors of mortality) together with the monocyte to lymphocyte ratio (resulting from secondary analysis).
our genotyped cohort of 427 patients, including after correction for possible confounding factors, such as disease severity, as measured by GCS score. Late presentation, which increases mortality, might confound a possible effect of the LTA4H genotype, and we therefore separately analyzed patients with milder disease. Those with the TT genotype showed a trend toward better survival, so an effect in this subgroup cannot be excluded. Unlike the Vietnam study, we could not stratify the effect of LTA4H genotype on the basis of corticosteroid treatment, as all patients received adjuvant corticosteroids according to international guidelines. Our findings suggest that more study is needed to understand the effect of host genetic background on TBM treatment response and outcome, although it will be difficult to examine this specific association outside East Asia, owing to a lower prevalence of rs17525495 the TT LTA4H genotype (1000 Genomes Project; available at: http://www.internationalgenome.org/). Our study has several strengths, including its size, high rate of bacteriological confirmation, and complete data and follow-up. We used a somewhat more strict case definition than a consensus definition [26] , which still needs evaluation in different settings. Unfortunately, neuroimaging and neurosurgical interventions were not available in this cohort. Also, we have no verified treatment adherence. Finally, since our data are observational, it is difficult to distinguish causation from association.
In conclusion, this study strengthens the concept that damaging inflammation contributes to the presentation and poor outcome of TBM and suggests that neutrophils play an important role in this effect. Further immunological, gene expression, metabolic, and genetic studies could increase our understanding of immunopathology and help identify targets or genetic markers to guide host-directed therapy in patients with TBM.
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